

Virtual CEDA/FID Congress 2020

December 13-15, 2020

Belgrade, Serbia

Pre-final program

Sunday, December 13, 2020

Time	
17.00 – 17.30	Welcome addresses
17.30 – 19.00	Session 1. Glucose control, inflammation and chronic complications
	<i>Chairpersons:</i> <i>T. Stulnig (Vienna, Austria), P. Kempler (Budapest, Hungary)</i>
17.30	<i>T. Stulnig (Vienna, Austria)</i> Prevention and treatment of CVD in diabetes: how to start antyhyperglycemic treatment
17.50	<i>C. Herder (Dusseldorf, Germany)</i> Subclinical inflammation and early neuropathy
18.10	<i>P. Kempler (Budapest, Hungary)</i> Treatment of diabetic neuropathy: achievements and dilemmas
18.30	<i>J. Skrha (Prague, Czech Republic)</i> Glucose variability and microvascular diaseses in diabetes
18.50	Discussion

Monday, December 14, 2020

Time	
09.00 – 10.30	Session 2. New technologies in the treatment of diabetes
	<i>Chairpersons:</i> <i>R. Weitgasser (Salzburg, Austria), R. Lehmann (Zurich, Switzerland)</i>
09.00	<i>R. Weitgasser (Salzburg, Austria)</i> Glucose sensing: an important tool for achieving optimal metabolic control
09.20	<i>T. Klupa (Krakow, Poland)</i> The use of glucose sensing during physical activity in diabetic patients
09.40	<i>N.M. Lalić (Belgrade, Serbia)</i> Sensor augmented pumps: benefits and uncertainties
10.00	<i>R. Lehmann (Zurich, Switzerland)</i> Islet transplantation vs insulin pump therapy
10.20	Discussion

10.30 – 11.00 Break

Time	
11.00 – 12.30	Session 3. COVID-19 and diabetes
	<i>Chairpersons:</i> <i>A. Ceriello (Milan, Italy), A. Janež (Ljubljana, Slovenia)</i>
11.00	<i>A. Ceriello (Milan, Italy)</i> The lessons from COVID-19 pandemic: how to design the treatment of diabetes
11.20	<i>A. Stoian (Bucharest, Romania)</i> Incretin-based therapies in COVID-19 patients with diabetes
11.40	<i>A. Janež (Ljubljana, Slovenia)</i> Insulin treatment in COVID-19 patients with diabetes
12.00	Discussion

12.30 – 14.00 Break

Time	
14.00 – 15.30	Session 4. Oral presentations
	TBD

15.30 – 16.00 Break

Time	
16.00 – 17.15	Session 5. Fatty liver, obesity and lipids in diabetes: new treatments
	<i>Chairpersons:</i> <i>M. Roden (Dusseldorf, Germany), T. Tankova (Sofia, Bulgaria)</i>
16.00	<i>M. Roden (Dusseldorf, Germany)</i> Fatty liver disease: new therapeutic possibilities
16.20	<i>T. Tankova (Sofia, Bulgaria)</i> Pharmacological treatment of obesity: recent advances
16.40	<i>K. Lalić (Belgrade, Serbia)</i> LDL cholesterol target: is it still the lower the better?
17.00	Discussion

Time	
17.15 – 18.30	CEDA/FID Board Meeting

Tuesday, December 15, 2020

Time	Hall A
09.00 – 10.30	Session 6. Hypoglycemia in diabetes treatment: an update
	<i>Chairpersons:</i> <i>A. Mitrakou (Athens, Greece), T. Milenković (Skopje, N. Macedonia)</i>
09.00	<i>A. Mitrakou (Athens, Greece)</i> Hypoglycemia in the context of new therapies in type 2 diabetes
09.20	<i>D. Rahelić (Zagreb, Croatia)</i> Mediterranean diet and exercise: the effect on glucose control and metabolic syndrome parameters
09.40	<i>T. Milenković (Skopje, N. Macedonia)</i> Education as a tool to avoid hypoglycemia in diabetes
10.00	Discussion

10.30 – 11.00 Break

Time	
11.00 – 12.30	Session 7. Pregnancy and reproduction in diabetes
	<i>Chairpersons:</i> <i>E. Hatziagelaki (Athens, Greece), Z. Kamenov (Sofia, Bulgaria)</i>
11.00	<i>E. Hatziagelaki (Athens, Greece)</i> PCO and diabetes: how to use the biomarkers
11.20	<i>A. Jotić (Belgrade, Serbia)</i> Treatment of diabetes in pregnancy: new technologies and their impact
11.40	<i>Z. Kamenov (Sofia, Bulgaria)</i> Erectile dysfunction in diabetes: an update on diagnosis and treatment
12.00	Discussion

Time	
12.30 – 13.30	General Assembly

13.30 **Closing**

Time	
16.00 – 17.30	Satelite symposium – sponsor Novo Nordisk